The data revealed the product to be well tolerated and efficacious in certain age groups and at certain time points.
“It is very difficult to change a healthy barrier and therefore the data showing improvement in some age groups gives us confidence in our partner discussions, and in seeking to develop future applications in disease conditions where the barrier is known to be poor such as eczema,” O’Neill said.
The readout showed that the under 50s group saw a statistically significant increase in skin hydration at day 15, though at day 29 there was no difference in hydration across all the groups monitored.
There was also a small, but statistically significant decrease in transepidermal water loss at day 29 in the over 60s cohort.
“To show efficacy at this stage of development is very exciting since there is a lot of scope for us to further optimise the formulation, potentially altering the dose of the SkinBiotix to make it more suitable for different age groups,” said CEO O’Neill.